The 340B Drug Pricing Program allows safety net health care entities to access discounts on medications they provide, and to use the savings to invest in expanded programs and services. This study characterizes current use of the 340B Program by health care entities that serve people living with HIV and vulnerable to HIV in California, and assesses possible changes to current HIV‐related care that may occur if a recent proposal by Gov Brown to eliminate discounts on Medi-Cal transactions is enacted. Our findings strongly support maintaining access to robust 340B savings as a vital source of support for comprehensive HIV-related services.
Send this to a friend